# EDGAR Filing Document

**Accession Number:** 0001106644
**File Stem:** 0001213900-23-014316
**Filing Date:** 2023-2
**Character Count:** 8824
**Document Hash:** 4bc4f9cba3d44c945c366a35c5e8127c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-014316.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001213900-23-014316

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230224

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CHINA PHARMA HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001106644
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 731564807
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34471
- **FILM NUMBER:** 23667013

**BUSINESS ADDRESS:**
- **STREET 1:** 2ND FLOOR, NO. 17, JINPAN ROAD
- **STREET 2:** HAIKOU
- **CITY:** HAINAN PROVINCE
- **STATE:** F4
- **ZIP:** 570216
- **BUSINESS PHONE:** 8689866811730

**MAIL ADDRESS:**
- **STREET 1:** 2ND FLOOR, NO. 17, JINPAN ROAD
- **STREET 2:** HAIKOU
- **CITY:** HAINAN PROVINCE
- **STATE:** F4
- **ZIP:** 570216

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TS ELECTRONICS INC
- **DATE OF NAME CHANGE:** 20030818

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SOFTSTONE INC
- **DATE OF NAME CHANGE:** 20030128

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SOFTSTONE INC /DE/
- **DATE OF NAME CHANGE:** 20010808

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 24, 2023**

**CHINA PHARMA HOLDINGS, INC.**

(Exact name of Registrant as specified in charter)

<u>Nevada</u> <u>001-34471</u> <u>73-1564807</u> <br> (State or other jurisdiction (Commission File No.) (IRS Employer <br> of Incorporation) Identification No.)

---

| | |
|:---|:---|
| **Second Floor, No. 17, Jinpan Road**<br> **Haikou, Hainan Province, China** | **570216** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: <u>+86 898-6681-1730 (China)</u>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

☐ Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | CPHI | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure**

On February 24, 2023, China Pharma Holdings, Inc. issued a press release, included herewith as Exhibit 99.1, announcing that it expects to implement a 1-for-10 reverse stock split effective Monday, March 6, 2023, with trading to begin on a split-adjusted basis at the market open on that day.

The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits**

(d) *Exhibits.*

99.1 [Press Release, dated February 24, 2023.](ea174228ex99-1_chinapharma.htm) <br>104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 24, 2023

---

| | |
|:---|:---|
| **CHINA PHARMA HOLDINGS, INC.** | **CHINA PHARMA HOLDINGS, INC.** |
| By: | /s/ Zhilin Li |
| Name:<br> Title: | Zhilin Li <br>President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split** 

**Haikou City, China**, **February 24, 2022 – China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI)** reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Monday, March 6, 2023, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-203.

The reverse stock split at a ratio of 1-for-10 shares was approved by the Company's Board of Directors through unanimous written consent and the Company's stockholders through Annual Meeting for the fiscal year ended on December 31, 2021, which was held on December 27, 2022.

Upon the effectiveness of the reverse stock split, every 10 shares of the Company's issued and outstanding common stock will automatically be converted into one share of issued and outstanding common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split will be rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's outstanding common stock, except for adjustments that may result from the treatment of fractional shares.

**About China Pharma Holdings, Inc.** 

China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company that develops, manufactures, and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

**Safe Harbor Statement** 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.

**For more information, please contact Investor Relations:**

China Pharma Holdings, Inc.

Ms. Diana Na Huang

Phone: +86-898-6681-1730 (China)

Email: hps@chinapharmaholdings.com